There was a time when the closest that Christofer Toumazou thought he would get to the hallowed halls of Imperial College, London, was when he was walking down Exhibition Road on the way to the Science Museum with the workshops of the esteemed institution visible on his right.
However, at the age of 23, and without an “O” level or “A” level, let alone an Oxbridge degree on his CV, the young engineer was accepted for a postdoctoral position at the university, beginning a career that would lead to him creating an artificial pancreas for people with diabetes, a wireless heart monitor and a combined digital and analogue mobile phone, among other inventions.
However, it is his latest creation that has prompted the most interest and which in June earned him a European inventor award.
His development of a small silicon microchip in a USB stick — dubbed a “lab on a chip” — has allowed DNA data to be analyzed within minutes and outside a laboratory. This new technology is aimed at identifying a predisposition for such hereditary diseases as diabetes, and at prescriptions that have the exact dosage for medication, cutting down on the cost of DNA testing machines.
“My dream was to have a handheld consumer device with ... a little USB stick that could look at rapidly screening for genetic mutations of particular diseases, whether it is a predisposition to Type 2 diabetes [or] whether a type of breast cancer,” Toumazou said in his office at the Institute of Biomedical Engineering at Imperial College.
The new DNA analysis method is the latest installment in a far-from-traditional career path for the Greek Cypriot. Having left school in Cheltenham in southwest England at 16 with a “few CSEs [Certificates of Secondary Education],” the most typical route for him to have followed would have been in the family catering business. However, he became inspired by an aunt’s engineer husband and developed an interest in electrical engineering.
Encouraged to do a one-year radio and electronics certificate — when the “whole Greek Cypriot contingent of Cheltenham turned up” on his first day — he found the environment in which he wanted to thrive. He did a two-year general engineering course, a degree at Oxford’s polytechnic, and later a doctorate. By the age of 23, he had applied for a postdoctoral position at Imperial College and was offered it the same day.
MEDICAL TECHNOLOGY
The position involved working with industry to reduce the size of satellite phones at a time when his interest was in analogue — speech, sound and vision — electronics.
Former Thai prime minister Thaksin Shinawatra, who at the time ran a mobile phone operator, asked him in the 1990s to make a combined digital and analogue mobile phone; that project led to the establishment of Toumaz Technology, a commercial spinoff.
Toumazou’s next inspiration came in combining biological and electronic elements, working on cochlear implants, research that directed him toward healthcare.
“I was very keen on bringing medical-grade technology to the consumer,” he said.
Later came the Sensium, a processor termed a “digital plaster” that could monitor vital signs — the heart rate, respiration and temperature — of patients, then send that data to a nurses’ station, cutting down on intervals between observations and aiding prioritization of patients in hospital accident and emergency departments.
At about the same time, his son Marcus had renal failure at the age of nine.
“For the first time I was on the receiving side of what medical technology was like, rather than being in a plush environment trying to develop all these super-duper widgets and gadgets, and it really, really, frightened me,” he said.
TURNING POINT
This experience led him to focus on technology that could detect hereditary diseases like that suffered by his son. While advancements in technology might not be able to prevent such a disease, they might help better manage the condition, he said.
Describing his DNA analysis system as his “simplest invention, but most significant,” Toumazou said he focused on how humans differ from other humans by 0.1 percent. That difference, he said, showed whether people could metabolize certain drugs properly and whether there were genetic conditions present that differed in any way.
His invention uses small silicon microchips that can identify genetic differences that dictate a person’s inclination to hereditary diseases such as diabetes and how people will react to a drug like warfarin, which is used to treat blood clots.
To use the “lab on a chip” system, a sample of saliva or a swab from inside the mouth is taken and put inside a container with the chip inside. The chip is then put inside a USB stick and plugged into a computer. The DNA results are returned within about 30 minutes, Toumazou said.
One of the main benefits is the speed of the information path, he said. In situations where a drug is needed to counter a hospital-based infection, the new technology can help determine which drug is needed in a short space of time, cutting out the waiting and potential risk of fatality, he added.
The cost savings, compared with conventional DNA-sequencing machines, open up the possibility for using the technology in areas such as sub-Saharan Africa, where clinics can be poorly equipped.
DNA Electronics, the company set up by Toumazou to develop the technology, licenses its patents to other companies, including Roche, Life Technologies, and the UK’s National Institute for Health Research of the National Health Service.
The technology has also been licensed to Geneu, a cosmetics firm with an office in New Bond Street, London, where bespoke products billed as anti-aging are created based on DNA testing.
Toumazou said “real science” would achieve recognition in that industry where so much “placebo science” exists.
“If it gets recognized, it will help with my big picture of getting consumer acceptance. It takes the stigma away from it being a medial device — and then I can go back to the big picture,” he said.
Two sets of economic data released last week by the Directorate-General of Budget, Accounting and Statistics (DGBAS) have drawn mixed reactions from the public: One on the nation’s economic performance in the first quarter of the year and the other on Taiwan’s household wealth distribution in 2021. GDP growth for the first quarter was faster than expected, at 6.51 percent year-on-year, an acceleration from the previous quarter’s 4.93 percent and higher than the agency’s February estimate of 5.92 percent. It was also the highest growth since the second quarter of 2021, when the economy expanded 8.07 percent, DGBAS data showed. The growth
In the intricate ballet of geopolitics, names signify more than mere identification: They embody history, culture and sovereignty. The recent decision by China to refer to Arunachal Pradesh as “Tsang Nan” or South Tibet, and to rename Tibet as “Xizang,” is a strategic move that extends beyond cartography into the realm of diplomatic signaling. This op-ed explores the implications of these actions and India’s potential response. Names are potent symbols in international relations, encapsulating the essence of a nation’s stance on territorial disputes. China’s choice to rename regions within Indian territory is not merely a linguistic exercise, but a symbolic assertion
More than seven months into the armed conflict in Gaza, the International Court of Justice ordered Israel to take “immediate and effective measures” to protect Palestinians in Gaza from the risk of genocide following a case brought by South Africa regarding Israel’s breaches of the 1948 Genocide Convention. The international community, including Amnesty International, called for an immediate ceasefire by all parties to prevent further loss of civilian lives and to ensure access to life-saving aid. Several protests have been organized around the world, including at the University of California Los Angeles (UCLA) and many other universities in the US.
Every day since Oct. 7 last year, the world has watched an unprecedented wave of violence rain down on Israel and the occupied Palestinian Territories — more than 200 days of constant suffering and death in Gaza with just a seven-day pause. Many of us in the American expatriate community in Taiwan have been watching this tragedy unfold in horror. We know we are implicated with every US-made “dumb” bomb dropped on a civilian target and by the diplomatic cover our government gives to the Israeli government, which has only gotten more extreme with such impunity. Meantime, multicultural coalitions of US